NCT02757248View on ClinicalTrials.gov

Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

November 30, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions

PTCLCTCL

Interventions

DRUG

Volasertib

Volasertib 75-150mg/m2 given intravenously on days 1 and 8

DRUG

Romidepsin

Romidepsin 12-14mg/m2 given intravenously on days 1, 8 and 15

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

National Comprehensive Cancer Network

NETWORK

collaborator

Boehringer Ingelheim

INDUSTRY

lead

Anne Beaven, MD

OTHER